Collaboration Agreement - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2021	Feb. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments receivable	$ 135,000,000.0
Combined performance obligation			$ 8,300,000		$ 8,300,000
Development activities performance obligation			3,700,000		3,700,000
Deferred Revenue			15,363,000		15,363,000		$ 11,715,000
Collaboration revenue			359,000	$ 14,000	1,352,000	$ 14,000
Material impact on revenue recognition, amendment			0		0
Clinical Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 12,000,000.0
Upfront payment recognition in future periods to settlement of obligation			12,000,000.0		$ 12,000,000.0
Deferred revenue, description					Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.3 million to the Combined Performance Obligation and $3.7 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.4 million to the Combined Performance Obligation and $1.6 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of September 30, 2022, as all milestone amounts were fully constrained based on the probability of achievement. The Company and LianBio amended the LianBio License Agreement on September 26, 2022, to allow, among other things, LianBio to conduct its own Phase 3 clinical trial and adjust certain future milestones. The amendment also requires both parties to negotiate a supply agreement prior to December 31, 2022. The amendment did not result in any change in the Company’s determination of its performance obligations under the arrangement and all future milestones remain constrained from the transaction price. The Company has determined that the contract modification did not have a material impact on the allocation of the transaction price to the two performance obligations.
Revenue related to the achievement of the milestone catch up adjustment					$ 100,000
Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue			300,000	14,000	900,000	14,000
Milestone Achievements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation		$ 5,000,000.0	5,000,000		5,000,000
Combined performance obligation		3,400,000	3,441,000		3,441,000
Development activities performance obligation		1,600,000	1,559,000		1,559,000
Collaboration revenue		5,000,000.0	100,000	$ 0	500,000	$ 0
Pre-Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation		12,000,000.0	12,000,000		12,000,000
Combined performance obligation			8,259,000		8,259,000
Development activities performance obligation			3,741,000		3,741,000
Post-Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation		$ 17,000,000.0	17,000,000		17,000,000
Combined performance obligation			11,700,000		11,700,000
Development activities performance obligation			$ 5,300,000		$ 5,300,000